investigation the effectiveness of simultaneous administration of L-carnitine and aerobic exercise compared to placebo and aerobic exercise on changes in the ultrasound grade of fatty liver and liver enzyme levels in patients with non-alcoholic fatty liver

Start Date20 Jan 2025

Sponsor / Collaborator

Hamedan University of Medical Sciences

IRCT20240624062239N1

/ SuspendedNot ApplicableIIT

Investigating the effectiveness of L-carnitine on heart failure patients

Start Date21 Dec 2024

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

IRCT20241112063688N1

/ RecruitingPhase 3IIT

Investigating the effect of L-carnitine on the improvement of fatigue in cancer patients receiving platinum-based chemotherapy regimens: a clinical trial study

Start Date05 Dec 2024

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

100 Clinical Results associated with Levocarnitine

100 Translational Medicine associated with Levocarnitine

100 Patents (Medical) associated with Levocarnitine

8,457

Literatures (Medical) associated with Levocarnitine

31 Dec 2025·VETERINARY QUARTERLY

Metabolomics reveals alterations in gut-derived uremic toxins and tryptophan metabolism in feline chronic kidney disease

Article

Author: Van Mulders, Laurens ; Mortier, Femke ; Vanhaecke, Lynn ; Vanden Broecke, Ellen ; Daminet, Sylvie ; De Paepe, Ellen

Chronic Kidney Disease (CKD) is one of the most common conditions affecting felines, yet the metabolic alterations underlying its pathophysiology remain poorly understood, hindering progress in identifying biomarkers and therapeutic targets. This study aimed to provide a comprehensive view of metabolic changes in feline CKD across conserved biochemical pathways and evaluate their progression throughout the disease continuum. Using a multi-biomatrix high-throughput metabolomics approach, serum and urine samples from CKD-affected cats (n = 94) and healthy controls (n = 84) were analyzed with ultra-high-performance liquid chromatography-high-resolution mass spectrometry. Significant disruptions were detected in tryptophan (indole, kynurenine, serotonin), tyrosine, and carnitine metabolism, as well as in the urea cycle. Circulating gut-derived uremic toxins, including indoxyl-sulfate, p-cresyl-sulfate, and trimethylamine-N-oxide, were markedly increased, primarily due to impaired renal excretion. However, alternative mechanisms, such as enhanced bacterial formation from dietary precursors like tryptophan, tyrosine, carnitine, and betaine, could not be ruled out. Overall, the findings suggest that metabolic disturbances in feline CKD are largely driven by the accumulation of gut-derived uremic toxins derived from precursors highly abundant in the feline diet. These insights may link the strict carnivorous nature of felines to CKD pathophysiology and highlight potential avenues for studying preventive or therapeutic interventions.

31 Dec 2025·Gut Microbes

Gut microbes with the gbu genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition

Article

Author: Wang, Jin-Town ; Lo, Yi-Ling ; Yen, Jeffrey J. Y. ; Kuo, Han-Chun ; Kao, Hsien-Li ; Hsu, Chia-Lang ; Sheen, Lee-Yan ; Chen, Yi-Hsun ; Hsu, Cheng-Chih ; Liao, Yu-Chieh ; Lo, I-Hsuan ; Panyod, Suraphan ; Kuo, Ching-Hua ; Zou, Hsin-Bai ; Yang, Yu-Tang ; Chiu, Jian-Ying ; Wu, Ming-Shiang ; Chuang, Hsiao-Li ; Wu, Wei-Kai ; Chiu, Tina H. T. ; Chiu, Han-Mo

Gut microbial metabolism of L-carnitine, which leads to the production of detrimental trimethylamine N-oxide (TMAO), offers a plausible link between red meat consumption and cardiovascular risks. Several microbial genes, including cntA/B, the cai operon, and the recently identified gbu gene cluster, have been implicated in the conversion of dietary L-carnitine into TMA(O). However, the key microbial genes and associated gut microbes involved in this pathway have not been fully explored. Utilizing the oral carnitine challenge test (OCCT), which specifically measures TMAO production from L-carnitine intake and identifies TMAO producer phenotypes, we compared the abundance of microbial genes between low- and high-TMAO producers across three independent cohorts. Our findings consistently revealed that the gbu gene cluster, rather than cntA/B or the cai operon, was significantly enriched in high-TMAO producers. We further analyzed 292 paired multi-omic datasets from OCCT and shotgun metagenomic sequencing, which demonstrated a significant positive correlation between the abundance of fecal gbu genes and L-carnitine-induced TMAO production, with gbuB showing the strongest correlation. Interestingly, these fecal gbu genes were found to increase with L-carnitine supplementation and decrease with a plant-based diet. Notably, we verified a previously uncultured gbu-containing bacterium, JAGTTR01 sp018223385, as the major contributor to TMA formation in the human gut. We isolated these gbu-containing gut microbes and confirmed their role in TMA/TMAO production using anaerobic incubation and a gnotobiotic mouse model. Using an in-house collection of gbu-containing isolates, we developed a qPCR-based method to quantify fecal gbuB and validated its correlation with L-carnitine-mediated TMAO production as measured by OCCT. Overall, these findings suggest that gbu-containing gut microbes are crucial for TMAO increases following L-carnitine intake and may serve as biomarkers or targets for personalized nutrition.

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Identification of a biallelic MMUT variant (p.Thr230Arg) and its global perspective on clinical management

Article

Author: Azam, Maleeha ; Khan, Sabeen Abid ; Qamar, Raheel ; Ali, Qamar ; Mansoor, Sumreena ; Malik, Munir Iqbal ; Imran, Muhammad

BACKGROUND:

Methylmalonic acidemia (MMA), type mut (0) is a rare type of genetic inborn error of metabolism (IEM) that is caused by aberrant malonyl-CoA mutase activity. Diagnosing IEM can be challenging due to its inherited onset and varying degrees of severity.

METHODS AND RESULTS:

In the present study, a consanguineous Pakistani family suspected of IEM was genetically analyzed using whole exome sequencing. A biallelic variant c.689 C > G (p.Thr230Arg) in MMUT was identified to be the causative factor of the disease, which helped in establishing the accurate diagnosis in the family to be MMA mut(0) type. On the basis of the genetic findings, the patient's condition was appropriately managed through a supportive nutrition plan and administration of oral L-carnitine.

CONCLUSIONS:

Identification of MMUT mutation through whole exome sequencing was helpful in solving the family and devising targeted management strategies. This study highlights the utility of genetic analysis in diagnosing and treating metabolic disorders like MMA in Pakistani inbred population.

News (Medical) associated with Levocarnitine

12 Nov 2024

·www.prnewswire.com

2024 Tsingke High-Impact Literature Compilation - Gene Synthesis

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number of high-level academic papers published using Tsingke's products and services has grown steadily year after year, continuously driving the advancement of life science research. We have selected two high-impact papers, published in prestigious journals, spanning a range of fields from gene function research to immunotherapy. Compilation of High-Impact Literature 1. Title: Enhancing rice panicle branching and grain yield through tissue-specific brassinosteroid inhibition DOI: 10.1126/science.adk8838 Journal: Science Impact Factor: 56.9 Summary: This study shows that crop yield potential is limited by inherent trade-offs between grain size and number. While brassinosteroids (BRs) promote grain enlargement, their role in regulating grain number has been unclear. By analyzing a cluster-type rice germplasm, the researchers found that activating the BR metabolic gene BRASSINOSTEROID-DEFICIENT DWARF3 (BRD3) significantly increases grain number. A molecular pathway was established where the BR signal inhibitor GSK3/SHAGGY-LIKE KINASE2 phosphorylates and stabilizes the OsMADS1 transcription factor, which targets the TERMINAL FLOWER1-like gene RICE CENTRORADIALIS2. Tissue-specific activation of BRD3 in secondary branch meristems enhances panicle branching, reduces the negative impact on grain size, and improves grain yield. The study demonstrates the powerful role of tissue-specific hormone manipulation in overcoming trait trade-offs and unlocking rice yield potential. 2. Title: Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer DOI: 10.1038/s41392-024-01772-w Journal: Signal Transduction and Targeted Therapy Impact Factor: 39.3 Summary: Despite the success of immune checkpoint therapies, resistance and relapse remain common in lung cancer. Cancer stem cells (CSCs) are an important factor in immune therapy resistance. Ferroptosis, a form of cell death driven by iron-dependent lipid peroxidation, has shown synergistic effects with immunotherapy. This study shows that the key rate-limiting enzyme CPT1A in fatty acid oxidation, together with L-carnitine from tumor-associated macrophages, drives ferroptosis resistance and CD8+ T cell dysfunction in lung cancer. Mechanistically, CPT1A inhibits the ubiquitination and degradation of c-Myc, which transcriptionally activates CPT1A expression. The CPT1A/c-Myc positive feedback loop enhances the NRF2/GPX4 system and reduces the quantity of phospholipid polyunsaturated fatty acids, boosting cellular antioxidant capacity and suppressing ferroptosis in CSCs. Importantly, targeting CPT1A enhances anti-tumor immunity and ferroptosis in immune checkpoint blockade therapy in tumor-bearing mice. These results present a metabolic vulnerability-targeting approach to improve lung cancer immunotherapy efficacy. Tsynth™ Gene Synthesis Tsingke is built on a foundation of advanced gene synthesis technology, supported by a gene-smart molecular splitting and assembly platform that enhances accuracy and success rates. Leveraging years of expertise in life sciences, bioinformatics, and computer science, Tsingke has pioneered cutting-edge codon optimization techniques. At the same time, the company utilizes the propeller system (TSINGKE HELIXTECH), an integrated full-cycle management system that combines customer service, production management, and lean management. By employing AI algorithms, it effectively links raw materials, equipment, and processes, powering intelligent production lines and precise gene detection quality control techniques. This enables Tsingke to provide low-cost, high-efficiency, and high-quality gene synthesis services, meeting the needs of researchers in fields such as life science research, biopharmaceuticals, biological breeding, biomanufacturing, and gene storage. For more high-impact papers utilizing Tsingke's products and services, visit our website to explore how our solutions are helping advance research worldwide. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyGene Therapy

28 Oct 2024

·www.prnewswire.com

Cocrystal Health Industry Announces Launch of Best in Class Bioabsorption and Stability Cocrystallized Lutein and Curcumin Technologies

Patented and clinically verified nutraceutical actives outperform current branded offerings and offer a powerful solution for supplement product potency concerns. LAS VEGAS, Oct. 28, 2024 /PRNewswire/ -- At the Supplyside West tradeshow this week representatives from Cocrystal Health Industry are announcing the launch of the Cocrystal Lutein and Curcumin powder actives. Backed by 60 global patents and near 100 published papers, the company leverages their proprietary and clean cocrystallization platform to produce actives with dramatically improved bioabsorption, stability and functionality relative to existing offerings. These launches build on their existing cocrystallized ingredient portfolio which includes Ubiquinol CoQ10, Hydroxytyrosol and Alpha Tocopherol Vitamin E. Continue Reading Cocrystal Curcumin Powder Cocrystal Lutein Powder Lutein is well demonstrated in clinical research to support eye health, though traditional lutein ingredients have poor bioabsorption, solubility, and stability, as the ingredient is easily oxidized. Powered by Cocrystal Health Industry's clean, vegan and non-GMO cocrystallization process, Cocrystal Lutein now provides a powerful solution to address these concerns. In 3rd party testing, Cocrystal Lutein demonstrated over 6 times greater bioabsorption and 3 times better solubility compared to current marketed lutein. In a head-to-head capsule stability study, the cocrystal advantage is even more dramatic. Cocrystal Lutein maintained over 99% of potency in capsules after 30 days, while current marketed lutein maintained less than 2% of its original potency. In addition to performance advantages, the cocrystal technology offers a significant cost savings relative to well known branded lutein. While well researched to support a range of benefits including joint and cognitive health, marketed curcumin extracts are similarly limited by very poor bioavailability. Patented Cocrystal Curcumin featuring L-Carnitine as a ligand has been shown in studies to offer over 10X greater bioabsorption in comparison to current marketed curcumin. And while there are several enhanced bioavailability curcumin materials available, in a head-to-head study Cocrystal Curcumin showed significantly better bioabsorption even relative to an existing enhanced offer. Alex Mei, PhD, Cocrystal Health Industry's Founder & CEO commented, "We are thrilled to expand our portfolio and introduce powerful new solutions in our Cocrystal Lutein & Curcumin technologies. Our proprietary platform solves for multiple nutrition brand concerns – providing meaningful differentiation and unparalleled benefit performance to their consumers, while ensuring sustained potency against label claim. As the global leader in cocrystallized active ingredients, we're proud to offer these transformative solutions." To learn more manufacturers and formulators can reach out to [email protected]. About Cocrystal Health Industry: Backed by 60 global patents and near 100 published papers, Cocrystal Health Industry introduces cocrystal powder technologies as unprecedented solutions for poor stability and low bioavailability ingredients. With demonstrated best in class bioavailability and superior in-formula stability, our actives also feature pure nature integrity, improved solubility, dissolution, melting point and flowability versus existing offerings. Beyond their superior performance, Cocrystal actives typically offer a cost advantage relative to other branded ingredients. The company's growing portfolio includes Cocrystal Ubiquinol, Hydroxytyrosol, Alpha Tocopherol, Rutin and now Lutein and Curcumin. For more information visit . Media Contact: Jeff Avila 305-632-1733 [email protected] SOURCE Cocrystal Health Industry WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

16 Oct 2023

·www.prnewswire.com

Native Pet Expands Its Growing Portfolio with the Launch of The Daily, An All-In-One Premium Supplement

An everyday product formulated to enhance your dog's daily diet and make a real difference in their health ST. LOUIS, Oct. 16, 2023 /PRNewswire/ -- Native Pet, a leading pet supplement company, announced today the addition of its most powerful and advanced product yet, The Daily. Continuing to challenge the industry, the launch of The Daily lives up to The Native Pet Pact, the brand's unwavering commitment to making a real difference in your pets' health. After two years of development, The Daily comes to market offering a science-backed, everyday solution for your dog's well-being using only the highest-quality and most efficacious ingredients. Continue Reading An everyday product formulated to enhance your dog’s daily diet and make a real difference in their health. "After years of research and development, we're thrilled to introduce The Daily," said Dan Schaefer, CEO and co-founder of Native Pet. "This all-in-one supplement is the first of its kind, packing all the powerful ingredients your dog needs into one tasty and science-backed scoop. Since we know kibble only goes so far, we created The Daily to fit seamlessly into your pet's daily routine and support them through all phases of their tail-wagging lives." Offering a solution for a category composed of mostly soft chews, The Daily's unique powder format ensures the integrity of the active ingredients and the highest level of efficacy for dogs. The new super supplement was formulated with the cleanest label possible, providing real, whole-food ingredients, zero additives or fillers, and the highest number of active ingredients on the market. Pat Barron, Native Pet COO and co-founder added, "We worked hand-in-hand with a team of vet nutritionists, veterinarians, and food scientists, and we're proud to introduce this everyday wellness supplement to support the most common ailments in canine health. We are committed to formulating only the very best products for our pets, which means developing proprietary formulas and hand-selecting ingredients." Barron further explains, "When formulating The Daily, we tapped into powerful active ingredients with Probiotics, L-Carnitine, and Zinc along with more familiar ingredients like Goat Milk, Bone Broth, and Pumpkin to ensure we're making the greatest impact for canine health and wellness." With 11 benefits in just one tasty scoop, The Daily's powerful blend of ingredients work together to support energy utilization, skin and coat health, mobility, gut health, and beyond. The launch of The Daily not only marks an exciting milestone for the brand portfolio, but also solidifies the demand for wider accessibility to Native Pet's products. The brand can now be found in nearly 2,000 retail locations, including 600 Target stores and over 1,000 Petco Pet Care Centers nationwide. Native Pet's continued partnership with Target and expansion into Petco further cements the brand as a leader in the growing market category and supports pet parents everywhere in prioritizing their dogs' health. The Daily is now available online at nativepet.com, Chewy, Amazon, and select Target stores. For more information, visit nativepet.com or follow @nativepet on Instagram and TikTok. About Native Pet Native Pet is committed to developing proprietary formulas and formats, offering only the best, most innovative supplements to directly benefit the health of pets. In an industry that has never prioritized the health of our pets, Native Pet is redefining the bar and holds true to its motto that "we're the voice of our pets and it's our mission to give our fur babies the best lives. Because our love language is dog, and dog is our native tongue." Media Contact [email protected] SOURCE Native Pet

100 Deals associated with Levocarnitine

External Link

KEGG	Wiki	ATC	Drug Bank
D02176	Levocarnitine	A16AA01	DB00583

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kidney Diseases	IT	Alfasigma SpA	18 May 2015
Shock, Septic	IT	Alfasigma SpA	18 May 2015
Cardiovascular Diseases	CN	Leadiant Biosciences, Inc.	31 Dec 1999
Metabolism, Inborn Errors	IE	Shire Pharmaceutical Development Ltd.	23 Oct 1996
Carnitine palmitoyltransferase deficiency	NL	Sigma-Tau Industrie Farmaceutiche Riunite SpA	03 Feb 1986
Systemic Carnitine Deficiency	US	Leadiant Biosciences, Inc.	27 Dec 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Phase 3	EG	Tanta University	05 Mar 2023
Pain	Phase 3	EG	Tanta University	05 Mar 2023
Rheumatoid Arthritis	Phase 3	EG	Tanta University	05 Mar 2023
Moderate persistent asthma	Phase 3	EG	Tanta University	08 Aug 2022
Persistent asthma	Phase 3	EG	Tanta University	08 Aug 2022
Beta-Thalassemia	Phase 3	EG	Tanta University	08 Jul 2022
Heart Failure	Phase 3	CN	Lee's Pharmaceutical Holdings Ltd.	01 Jan 2011
HMN (Hereditary Motor Neuropathy) Proximal Type I	Phase 2	US	Leadiant Biosciences, Inc.	01 Apr 2008
HMN (Hereditary Motor Neuropathy) Proximal Type I	Phase 2	CA	Leadiant Biosciences, Inc.	01 Apr 2008
HMN (Hereditary Motor Neuropathy) Proximal Type I	Phase 2	DE	Leadiant Biosciences, Inc.	01 Apr 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISN WCN2024	Not Applicable	L-carnitine \| levocarnitine	284	L-carnitine supplementation	gscgfpmowu(zbkzjeekjl) = ykmlqsvuyl bvsnrbkfru (nkbaxacnix, -10.29 to 4.13) View more	Negative	01 Apr 2024
NCT05083637 (Pubmed \| J Nutr)	Not Applicable	Malnutrition Myeloperoxidase \| Neopterin \| alpha-1-antitrypsin ... View more	98	L-carnitine syrup (100 mg/kg/d)	whfhfrsgnx(xjakqvxiab) = fcksqkgrxw lbcjvydzig (ntmopjullb, -556.58 to 249.91)	Negative	01 Mar 2024
AASLD2023	Not Applicable	Hepatic Encephalopathy \| Hyperammonemia	-	Oral L-Carnitine	ejbcalkmws(utkzthyzpu) = nxvmkgpjti fdddwccwlp (rwpedphgbn ) View more	-	10 Nov 2023
ATS2023	Not Applicable	Valproic Acid Antenatal Infection	-	Valproate	nqwdogwqjy(cgnmaueafh) = hemodynamic instability, metabolic derangements, encephalopathy, and cerebral edema that can progress to coma and death jvttejxcgo (uzsyzoyjfx ) View more	-	21 May 2023
ESMO2022	Not Applicable	Head and Neck Neoplasms	150	L-carnitine 500mg	bgbchfoxft(kqfipwgafi) = efrbcoyepf hydnwabtla (uioilhlikz )	-	10 Sep 2022
				L-carnitine (Control)	bgbchfoxft(kqfipwgafi) = weupkoshvt hydnwabtla (uioilhlikz )
NCT01783041 (CTgov)	Phase 2/3	Systemic Carnitine Deficiency \| Obstetric Labor, Premature \| Neurodevelopmental Disorders	144	5% dextrose (5% Dextrose)	mlfoebeimb(dxeujrzzem) = ohpzcpifmd usgmfwvcoa (nhzsbupwuq, tooongxsum - tamtlierju) View more	-	08 Mar 2022
				L-carnitine (L-carnitine)	mlfoebeimb(dxeujrzzem) = cdxlvojzpc usgmfwvcoa (nhzsbupwuq, wiaaeuiowb - rclhuvyfwm) View more
ESC2021	Not Applicable	Burns, Electric KCNH2-N588K	-	L-Carnitine	vilshvrsxs(oohfnfhazh) = xhgankqirp olhzhnmaak (pmpbtmjfey ) View more	-	29 Aug 2021
				L-Carnitine	vilshvrsxs(oohfnfhazh) = qzzbuchkkp olhzhnmaak (pmpbtmjfey )
ASN2019	Not Applicable	Peritoneal dialysis complication serum free carnitine (FC) \| acyl-carnitine (AC) \| urinary L-FABP ... View more	24	L-carnitine supplementation (750 mg/day)	vzymsxlmwi(qvxngstfvh) = vhtyvklepr ykkhkgcefq (rbwqqgrjwx ) View more	Positive	05 Nov 2019
				L-Carnitine (Control)	vzymsxlmwi(qvxngstfvh) = putrkachja ykkhkgcefq (rbwqqgrjwx ) View more
IC 172 (ASN2019)	Not Applicable	Hodgkin's Lymphoma Maintenance	172	Intravenous L-Carnitine (LC) 1000 mg	oekztkekja(oxvgvrcbjy) = bjvyjkxmxb hhxcaogqpz (iqcaczbfoj )	Positive	05 Nov 2019
UEGW2019	Not Applicable	Liver Cirrhosis	46	Levocarnitine < 1500 mg/day	mridsjhoxu(nfnxcmnkqk) = dnwemqemfg jgcnppnxfr (iqwjfjwphr, 52)	Positive	01 Oct 2019
				Levocarnitine 1500 mg/day or more	mridsjhoxu(nfnxcmnkqk) = pmxmpcqnzl jgcnppnxfr (iqwjfjwphr, 124)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis